Savara (SVRA) Preferred Dividend Payments (2010 - 2017)
Savara's (SVRA) quarterly Preferred Dividend Payments came in at $554000.0 in Q2 2017, up 27600.0% year-on-year from N/an in Q2 2016, and up 2208.33% on a QoQ basis from $24000.0 in Q1 2017.
Savara (SVRA) Preferred Dividend Payments (2010 - 2017) Analysis & Trends
Savara (SVRA) has 3 years of Preferred Dividend Payments data on file, last reported at $554000.0 in Q2 2017.
- On a quarterly basis, Preferred Dividend Payments rose 27600.0% year-over-year to $554000.0 in Q2 2017; TTM through Dec 2017 was $578000.0, a 94.91% decrease from a year earlier, with the FY2017 full-year figure at $578000.0, up 514.89% from the prior year.
- Preferred Dividend Payments for Q2 2017 stood at $554000.0, up from $24000.0 in the prior quarter.
- Over the last five years, Preferred Dividend Payments for SVRA reached as high as $554000.0 in Q2 2017 and fell as low as $2000.0 in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 554,000.00 |
| Mar 31, 2017 | 24,000.00 |
| Dec 31, 2016 | 24,000.00 |
| Sep 30, 2016 | 44,000.00 |
| Jun 30, 2016 | 2,000.00 |
| Dec 31, 2010 | 11.28 Mn |
| Jun 30, 2010 | -3.12 Mn |